The arrival of amivantamab offers a important development for people battling cancers exhibiting c-MET overexpression. This innovative antibody, a selective blocker of multiple MET kinase and also human epidermal growth factor receptor 2 (HER2), revealed preliminary effectiveness in patient assessments, particularly in patients whose tumors harbor